We would love to hear your thoughts about our site and services, please take our survey here.
Shear class gatemore have expressed their interest to sensyne in achieving a nasdaq listing and the below rns confirms that it is something sensyne are looking at
Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company's primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would be consistent with Sensyne's commitment to the ethical application of AI to patient data and its established strategic research agreements with the NHS and US health systems.
Some nice bits of info in that rns. Permits for 360000 tonnes of ore per year currently being sought to allow 1000 tpd permits will be in place before we reach the milestone. And average 9grams per tonne from east ramp. Sounds like the ship is in order
Personally I don’t think we will see another fund raise on a U.K. market. If there is an ipo on nasdaq then yes. We had plenty of cash in the bank I think 23million at April 2021 and have since signed commercial contracts. There should be more of these coming and if we do end up on the nasdaq then the fund raise will likely be outweighed by the positives of listing in America.
The pharma stocks over there can do silly multiples in a day and I think we are a unique company with a concept that doesn’t take much to grasp so the interest should be widespread if the ipo is marketed properly - I am sure the board are capable.
Cantab to be used in a schizophrenia trial with a repeat client, £600k over 3 years. Not to be sniffed at!
I like the way this company produces their rns releases, they are never cryptic with figures or information they just give you the facts and it’s all we need. Good luck
I thought perhaps we were being shorted but according to short trackers online there are no positions over 0.5% open.
Could the share price be being held down for a potential takeover? This question crossed my mind but surely confidentiality for patient data would be a very sticky situation if for instance a large pharmaceutical company were to take over. I cannot fathom how this is back at below placing level. The only blessing is the opportunity to average down.
Doubled patient record that means we should be going up 100% doesn’t it? In all seriousness it’s good to see we are moving fast in the US and working with what appear to be the best in class companies.
Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI
Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines
The Teaming Agreement allows OMNY to engage Sensyne's data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health's 22 million de-identified patient records
Dover, DE and Atlanta, GA. Oxford, U.K. October 15, 2021 : Sensyne Health plc (LSE: SENS) ("Sensyne"), the ethical Clinical AI company, and OMNY Health ("OMNY"), the largest US-based real world data network, today announced a strategic teaming relationship.
The arrangement establishes a nimble framework under which Sensyne can contract for access to OMNY Health's platform of more than 22 million de-identified patient records across all therapeutic areas in support of Sensyne's data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research. By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies-and their health system partners-will have more opportunities to support important life sciences research.
The OMNY data network complements Sensyne's existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK's National Health Service (NHS) trusts. With a data network that spans over 50,000 providers across 40 states, OMNY's data platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations. Sensyne will now have a new avenue to access an additional 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the combined total of de-identified patient data available for its research to over 44m patients.
Derek Baird, President, North America, Sensyne Health said:
"This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way. We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working to
Answers incorrect show some working out please try harder or the share price will keep rising.
I imagine this is how the deramping course tutor would mark such a poor piece of work.
2 for 1 reverse consolidation. Holders will receive 1 new Tiziana share for each old Tiziana they currently hold. New Tiziana will be tradeable on nasdaq only.
Old Tiziana delisted on 21/10 and new shares will be issued 14 days later.
I assume there will be another consolidation for the ipo to get the share price high enough to list on nasdaq?
A lot of big buys wonder if there will be a notification of an institution buying in tomorrow
Gatemore letter from July this year. Sounds like now with a bigger stake they will be pushing hard for nasdaq
https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf
Thread below this from yesterday says not. Hopefully he’s just confident of good results and topping up accordingly. It does seem cheap at the moment I’m just a bit too far under to dare buy any more dare I say it maybe when AccuStem shares arrive lol
I see someone took half a million at 140 today. Nice to see a move up
Agreed. Just finished the webinar recording and it was overall very positive I think this is purely a smear article from the times that unfortunately seems to have caught the imaginations of some investors.
Does this rule not apply to tils I thought now cerrone is over 30% he has to make an offer for the rest of the company?
There is a recording of the webinar on sensyne website not heard any talk of running out of funding so far.
Does anyone have a link to the actual interview? The times article does seem to paint him in a bad light. If we have so many contracts lined up as was mentioned in the results should we really need to be raising funds again?
boo hoo (AIM: BOO) , a leading online fashion retailer, is pleased to announce the appointment of Kirsty Britz to the Board as Non-Executive Director, with effect from today. Kirsty will become a member of the Audit and Risk Committees on appointment.
The appointment of Kirsty brings additional expertise to the Board, particularly in areas of Environmental, Social and Governance matters. Over the last twelve months the Group has significantly strengthened its Board with three Non-Executive Director appointments, resulting in a Board that comprises a majority of Independent Directors.
Kirsty is currently the Director of Sustainable Banking at NatWest Group plc and an independent member of the Professional Standards Committee at HMRC. Prior to joining NatWest Group, she held the role of Director of Citizenship at Barclays. Kirsty has served as a member of UKRI sustainability advisory group and as a member of NERC independent research panel and she has held various sustainability, brand strategy and marketing roles in the retail, telecommunications and advertising sectors.
Mahmud Kamani, Group Executive Chairman, commented:
"I am delighted to welcome Kirsty to the Board and look forward to the contribution she will bring. Her extensive ESG experience will help ensure the board remains focused on making balanced and sustainable decisions that factor in the impact of our strategy on multiple stakeholder groups."
Kirsty Britz, commented:
"I look forward to helping the Group develop its sustainability approach, embedding it into strategy, governance and operations, and ensuring the Board remains focused on building practices fit for a sustainable future."
Sounds like she’s got good experience where we need it. I wonder how long it will take the papers to stop digging once they realise we’ve nothing to hide now
Released mk2 of the portfolio programme today. 4 clients currently in trial period and more expected.
I had only read the highlights initially but when you go through the whole thing it reminds you of the volume of good news we’ve received this year. 25 commercial contracts lined up next year, I think I will buy more in 130s as this has to make a profit next year.